Acute lymphocytic leukemia (ALL) is the most predominant hematopoietic clonal disorder in children than adult. ALL classifies into two subtypes: B –ALLand T-ALL. The incidence of ALL subtype in urban areas is generally higher than rural areas. In the Western World, the predominant immunophenotype observed in ALL is B-ALL with 60-80% of total case, and T-ALL is only 15-20%. But in case of developing country like India the reverse is true. The objective of the present study is to examine and correlate T-ALL and B-ALL in leukemia patients with respect to socio-demographic factors.
During May 2015 - April 2017, total 427 ALL patients (male:female::1.9:1), age between 2-60 years attended OPD and IPD of Netaji Subhas Chandra Bose Cancer Research Institute, Kolkata, India. We have collected peripheral blood and/or bone marrow samples for immunophenotyping by FACS after taking written consent from the patients. Each sample is evaluated with a panel of monoclonal antibodies and compared the immunophenotyping data with socio-demographic factors (age, sex, economic and social status etc).
The overall survival of ALL patients (with mean age 13.6 years) in 2 year is 73.6%. In our hospital, the economically weak patients (77.05%) are more abundant than economically sound patients (22.95%). Out of 427 patients, T-ALL (51.28%) is predominantly higher than B-ALL (48.71%). We found that immunophenotyping data is correlated with all the socio demographic data i.e., sex, economic and social status etc. Though disease free survival and event free survival is markedly higher in B-ALL compared to T-ALL, but we found the survival of T-ALL is also increasing.
Our unique findings emphasize that the detection of T-ALL and B-ALL by immunophenotypic analysis for better treatment and outcome of the patients and also trying to correlate the prevalence of T-ALL and B-ALL with economical status and also with other socio-demographic factors in study area.
Clinical trial identification
Legal entity responsible for the study
Netaji Subhas Chandra Bose Cancer Research Institute
All authors have declared no conflicts of interest.